12:00 AM
Sep 27, 2010
 |  BC Week In Review  |  Company News  |  Deals

Reata, Abbott deal

Reata granted Abbott exclusive rights outside the U.S. and certain Asian markets to develop and commercialize bardoxolone for chronic kidney disease (CKD) and cardiovascular and metabolic indications. The small molecule activator of nuclear factor (erythroid-derived 2)-like 2 (...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >